Natural products for antithrombosis

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Chen, Cen ^a   Yang, Feng Qing ^a   Zhang, Qian ^a   Wang, Feng Qin ^a   Hu, Yuan Jia ^b   Xia, Zhi Ning ^a  

^a CHONGQING UNIVERSITY   (China)

^b University of Macau   (Macao)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARACHIDONIC ACID; NATURAL PRODUCT; THROMBOPLASTIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLOOD CLOTTING; CIRCULATION; DRUG MECHANISM; ESTROGEN THERAPY; FIBRIN FORMATION; FIBRINOLYSIS; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOSIS;

EID: 84930646722     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/876426     Document Type: Review

References (179)

1. B. Furie and B. C. Furie, "In vivo thrombus formation," Journal of Trombosis and Haemostasis, vol. 5, supplement 1, pp. 12-17, 2007.
2. A. J. Reininger, "VWF attributes-impact on thrombus formation," Trombosis Research, vol. 122, supplement 4, pp. S9-S13, 2008.
3. N. Mackman, "Role of tissue factor in hemostasis and thrombosis," Blood Cells, Molecules, and Diseases, vol. 36, no. 2, pp. 104-107, 2006.
4. Y. Ikeda, M. Handa, K. Kawano et al., "The role of von Willebrand factor and fbrinogen in platelet aggregation under varying shear stress," The Journal of Clinical Investigation, vol. 87, no. 4, pp. 1234-1240, 1991.
5. J.-L. Choi, S. Li, and J.-Y. Han, "Platelet function tests: a review of progresses in clinical application," BioMed Research International, vol. 2014, Article ID 456569, 7 pages, 2014.
6. W. C. Aird, "Vascular bed-specifc thrombosis," Journal of Trombosis and Haemostasis, vol. 5, supplement 1, pp. 283-291, 2007.
7. I. Hagedorn, T. Vögtle, and B. Nieswandt, "Arterial thrombus formation: novel mechanisms and targets," Hamostaseologie, vol. 30, no. 3, pp. 127-135, 2010.
8. B. Furie and B. C. Furie, "Mechanisms of thrombus formation," The New England Journal of Medicine, vol. 359, no. 9, pp. 938-949, 2008.
9. H. Z. Chen, "Advances in thrombolytic therapy," Foreign Medical Sciences, vol. 18, no. 2, pp. 50-54, 1991.
10. Y. C. Zhao, S. M. Zhao, G. Wang, and C. K. Zhang, "The recent development of third-generation thrombolytics," Progress in Pharmaceutical Sciences, vol. 28, no. 2, pp. 72-75, 2004.
11. S. P. Jackson, "Arterial thrombosis-insidious, unpredictable and deadly," Nature Medicine, vol. 17, no. 11, pp. 1423-1436, 2011.
12. A. G. G. Turpie and C. Esmon, "Venous and arterial throm-bosis-pathogenesis and the rationale for anticoagulation," Trombosis and Haemostasis, vol. 105, no. 4, pp. 586-596, 2011.
13. F. A. Spencer, C. Emery, S. W. Jofe et al., "Incidence rates, clinical profle, and outcomes of patients with venous thromboem-bolism. The Worcester VTE study," Journal of Trombosis and Trombolysis, vol. 28, no. 4, pp. 401-409, 2009.
14. A. C. Spyropoulos and J. Lin, "Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations," Journal of Managed Care Pharmacy, vol. 13, no. 6, pp. 475-486, 2007.
15. S. Çakarer, E. Eyüpoʇlu, Ç. Ö. Günes, B. G. Küseoʇlu, H. K. Berberoʇlu, and C. Keskin, "Evaluation of the hemostatic efects of ankaferd blood stopper during dental extractions in patients on antithrombotic therapy," Clinical and Applied Trombosis/Hemostasis, vol. 19, no. 1, pp. 96-99, 2013.
16. J. R. Simkhada, S. S. Cho, P. Mander, Y. H. Choi, and J. C. Yoo, "Purifcation, biochemical properties and antithrombotic efect of a novel Streptomyces enzyme on carrageenan-induced mice tail thrombosis model," Trombosis Research, vol. 129, no. 2, pp. 176-182, 2012.
17. Q. Ma, B. Dudas, A. Daud et al., "Molecular and biochemical profling of a heparin-derived oligosaccharide, C3," Trombosis Research, vol. 105, no. 4, pp. 303-309, 2002.
18. M. Mladenovíc, M. Mihailovíc, D. Bogojevíc et al., "Biochemical and pharmacological evaluation of 4-hydroxychromen-2-ones bearing polar C-3 substituents as anticoagulants," European Journal of Medicinal Chemistry, vol. 54, pp. 144-158, 2012.
19. C. Becattini and G. Agnelli, "Aspirin for prevention and treatment of venous thromboembolism," Blood Reviews, vol. 28, no. 3, pp. 103-108, 2014.
20. J. Wang, X. Xiong, and B. Feng, "Aspirin resistance and promoting blood circulation and removing blood stasis: current situation and prospectives," Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 954863, 11 pages, 2014.
21. E. Fuentes and I. Palomo, "Mechanism of antiplatelet action of hypolipidemic, antidiabetic and antihypertensive drugs by PPAR activation: PPAR agonists: new antiplatelet agents," Vascular Pharmacology, vol. 62, no. 3, pp. 162-166, 2014.
22. P. Sabouret and M. Taiel-Sartral, "New antiplatelet agents in the treatment of acute coronary syndromes," Archives of Cardiovascular Diseases, vol. 107, no. 3, pp. 178-187, 2014.
23. K. Butcher, A. Shuaib, J. Saver et al., "Trombolysis in the developing world: is there a role for streptokinase?" International Journal of Stroke, vol. 8, no. 7, pp. 560-565, 2013.
24. M. Gomaraschi, A. Ossoli, C. Vitali et al., "Of-target efects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase," Biochemical Pharmacology, vol. 85, no. 4, pp. 525-530, 2013.
25. "Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients," The British Medical Journal, vol. 324, no. 7330, p. 141, 2002.
26. N. E. Barrett, L. Holbrook, S. Jones et al., "Future innovations in anti-platelet therapies," British Journal of Pharmacology, vol. 154, no. 5, pp. 918-939, 2008.
27. M. Pirmohamed, S. James, S. Meakin et al., "Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients," British Medical Journal, vol. 329, no. 7456, pp. 15-19, 2004.
28. K. H. Ryu, H. Y. Han, S. Y. Lee et al., "Ginkgo biloba extract enhances antiplatelet and antithrombotic efects of cilostazol without prolongation of bleeding time," Trombosis Research, vol. 124, no. 3, pp. 328-334, 2009.
29. S. Bhanwra and K. Ahluwalia, "The new factor Xa inhibitor: apixaban," Journal of Pharmacology & Pharmacotherapeutics, vol. 5, no. 1, pp. 12-14, 2014.
30. M. Slevin, N. Ahmed, Q. Wang, G. McDowell, and L. Badimon, "Unique vascular protective properties of natural products: supplements or future main-line drugs with signifcant anti-atherosclerotic potential?" Vascular Cell, vol. 4, no. 1, article 9, 2012.
31. Z. Xiang, X. Wu, X. Liu, and Y. Jin, "Glaucocalyxin A: a review," Natural Product Research, vol. 28, no. 24, pp. 2221-2236, 2014.
32. I. T. Babalola, F. O. Shode, E. A. Adelakun, A. R. Opoku, and R. A. Mosa, "Platelet-aggregation inhibitory activity of oleanolic acid, ursolic acid, betulinic acid, and maslinic acid," Journal of Pharmacognosy and Phytochemistry, vol. 1, no. 6, pp. 54-60, 2013.
33. Y. Chang, S. K.-H. Huang, W.-J. Lu et al., "Brazilin isolated from Caesalpinia sappan L. acts as a novel collagen receptor agonist in human platelets," Journal of Biomedical Science, vol. 20, article 4, 2013.
34. F.-C. Cheng, W.-L. Chen, J.-W. Wei, K.-S. Huang, and G. G. Yarbrough, "The neuroprotective efects of BNG-1: a new formulation of traditional Chinese medicines for stroke," American Journal of Chinese Medicine, vol. 33, no. 1, pp. 61-71, 2005.
35. 2-induced aggregation in rabbit platelets," Biological & Pharmaceutical Bulletin, vol. 32, no. 5, pp. 856-860, 2009.
36. C. Li, X. Mao, and B. Xu, "Pulsed electric feld extraction enhanced anti-coagulant efect of fungal polysaccharide from Jew's ear (Auricularia auricula)," Phytochemical Analysis, vol. 24, no. 1, pp. 36-40, 2013.
37. Y.-R. Liao, Y.-L. Leu, Y.-Y. Chan, P.-C. Kuo, and T.-S. Wu, "Anti-Platelet aggregation and vasorelaxing efects of the constituents of the Rhizomes of Zingiber ofcinale," Molecules, vol. 17, no. 8, pp. 8928-8937, 2012.
38. I. Palomo, E. Fuentes, T. Padró, and L. Badimon, "Platelets and atherogenesis: Platelet anti-aggregation activity and endothelial protection from tomatoes (Solanum lycopersicum L.) (Review)," Experimental and Terapeutic Medicine, vol. 3, no. 4, pp. 577-584, 2012.
39. Y. Wang, H. Yan, H. Yang et al., "Proteomics and transcriptome analysis coupled with pharmacological test reveals the diversity of anti-thrombosis proteins from the medicinal insect, Eupolyphaga sinensis," Insect Biochemistry and Molecular Biology, vol. 42, no. 8, pp. 537-544, 2012.
40. Y. Liu, Study on the Knowledge Discovery From the 'Huoxue-huayu' TCM Database, Beijing University of Chinese Medicine, Beijing, China, 2006.
41. T. Yasuda, A. Takasawa, T. Nakazawa, J. Ueda, and K. Ohsawa, "Inhibitory efects of urinary metabolites on platelet aggregation afer orally administering Shimotsu-To, a traditional Chinese medicine, to rats," Journal of Pharmacy and Pharmacology, vol. 55, no. 2, pp. 239-244, 2003.
42. L. Gui, L. J. Guo, X. L. Xu, L. Qu, and C. Luo, "Efect of Kang Naoxueshuan tablet on protecting ischemic brain injury in rats," Chinese Journal of Integrative Medicine, vol. 26, supplement 1, pp. 7-10, 2006.
43. X. N. Li, J. Y. Yang, X. Pan et al., "Infuence of extract of Ginkgo biloba leaves tablets on the aquaporin-1 expression in isolated lung ischemia reperfusion," Chinese Medical Journal, vol. 126, no. 24, pp. 4720-4723, 2013.
44. E. Fuentes and I. Palomo, "Antiplatelet efects of natural bioac-tive compounds by multiple targets: food and drug interactions," Journal of Functional Foods, vol. 6, no. 1, pp. 73-81, 2014.
45. J. Z. Li, "Trombus formation mechanism," Journal of Clinical Internal Medicine, vol. 21, no. 12, pp. 793-795, 2004.
46. Q. Luo, H. Jin, and X. R. Tan, "Mechanism and treatment of thrombosis," Chinese Journal of Cardiovascular Rehabilitation Medicine, vol. 17, no. 1, pp. 83-85, 2008.
47. C. Dubois, L. Panicot-Dubois, G. Merrill-Skolof, B. Furie, and B. C. Furie, "Glycoprotein VI-dependent and-independent pathways of thrombus formation in vivo," Blood, vol. 107, no. 10, pp. 3902-3906, 2006.
48. R. G. Macfarlane, "An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifer," Nature, vol. 202, no. 4931, pp. 498-499, 1964.
49. A. H. M. Moons, M. Levi, and R. J. G. Peters, "Tissue factor and coronary artery disease," Cardiovascular Research, vol. 53, no. 2, pp. 313-325, 2002.
50. D. M. Monroe and N. S. Key, "The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking," Journal of Trombosis and Haemostasis, vol. 5, no. 6, pp. 1097-1105, 2007.
51. L. M. Lima, M. O. Sousa, L. M. S. Dusse, M. C. Lasmar, B. A. Lwaleed, and M. D. G. Carvalho, "Tissue factor and tissue factor pathway inhibitor levels in coronary artery disease: correlation with the severity of atheromatosis," Trombosis Research, vol. 121, no. 2, pp. 283-287, 2007.
52. Y. Nemerson, "Tissue factor and hemostasis," Blood, vol. 71, no. 1, pp. 1-8, 1988.
53. R. C. Becker, "Cell-based models of coagulation: a paradigm in evolution," Journal of Trombosis and Trombolysis, vol. 20, no. 1, pp. 65-68, 2005.
54. T. Orfeo, N. Brufatto, M. E. Nesheim, H. Xu, S. Butenas, and K. G. Mann, "The factor V activation paradox," The Journal of Biological Chemistry, vol. 279, no. 19, pp. 19580-19591, 2004.
55. M. E. Nesheim, J. B. Taswell, and K. G. Mann, "The contribution of bovine factor V and factor Va to the activity of prothrombi-nase," Journal of Biological Chemistry, vol. 254, no. 21, pp. 952-962, 1979.
56. G. Davì and C. Patrono, "Mechanisms of disease: platelet activation and atherothrombosis," The New England Journal of Medicine, vol. 357, no. 24, pp. 2482-2494, 2007.
57. R. K. Andrews, E. E. Gardiner, Y. Shen, and M. C. Berndt, "Platelet interactions in thrombosis," IUBMB Life, vol. 56, no. 1, pp. 13-18, 2004.
58. B. Savage, E. Saldívar, and Z. M. Ruggeri, "Initiation of platelet adhesion by arrest onto fbrinogen or translocation on von Willebrand factor," Cell, vol. 84, no. 2, pp. 289-297, 1996.
59. S. Ofermanns, "Activation of platelet function through G protein-coupled receptors," Circulation Research, vol. 99, no. 12, pp. 1293-1304, 2006.
60. D. S. Woulfe, "Platelet G protein-coupled receptors in hemosta-sis and thrombosis," Journal of Trombosis and Haemostasis, vol. 3, no. 10, pp. 2193-2200, 2005.
61. K. Broos, S. F. de Meyer, H. B. Feys, K. Vanhoorelbeke, and H. Deckmyn, "Blood platelet biochemistry," Trombosis Research, vol. 129, no. 3, pp. 245-249, 2012.
62. G. Vilahur and L. Badimon, "Antiplatelet properties of natural products," Vascular Pharmacology, vol. 59, no. 3-4, pp. 67-75, 2013.
63. J. Grotta, R. Ackerman, J. Correia, G. Fallick, and J. Chang, "Whole blood viscosity parameters and cerebral blood fow," Stroke, vol. 13, no. 3, pp. 296-301, 1982.
64. Y. J. Jin, "Trombosis and blood rheology," Journal of Microcirculation Technology, no. 4, pp. 214-216, 1993.
65. J. Gao, Z. L. Gu, and T. Y. Wang, "The relationship between blood stasis syndrome and hemorheology, and study progress on traditional Chinese medicines," Chinese Journal of Hemorhe-ology, vol. 13, no. 2, pp. 183-185, 2003.
66. Y. L. Li, Pathology, People's Medical Publishing House, Beijing, China, 2008, (Chinese).
67. P. A. Ringleb, "Trombolytics, anticoagulants, and antiplatelet agents," Stroke, vol. 37, no. 2, pp. 312-313, 2006.
68. S. M. Day, J. L. Reeve, B. Pedersen et al., "Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall," Blood, vol. 105, no. 1, pp. 192-198, 2005.
69. J. Stefel, M. Hermann, H. Greutert et al., "Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation," Circulation, vol. 111, no. 13, pp. 1685-1689, 2005.
70. E. Napoleone, A. Di Santo, and R. Lorenzet, "Monocytes upreg-ulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk," Blood, vol. 89, no. 2, pp. 541-549, 1997.
71. J. Stefel, A. Akhmedov, H. Greutert, T. F. Lüscher, and F. C. Tanner, "Histamine induces tissue factor expression: implications for acute coronary syndromes," Circulation, vol. 112, no. 3, pp. 341-349, 2005.
72. W. H. Xu, Y. D. Lv, P. H. Tao et al., "In vitro inhibitory efect of papain on blood coagulation function and the related mechanism," Chinese Clinical Pharmacology and Terapeutics, vol. 18, no. 2, pp. 166-170, 2013.
73. H. L. Ming, K. S. Yeon, and N. H. Yong, "Tissue factor inhibitory favonoids from the fruits of chaenomeles sinensis," Archives of Pharmacal Research, vol. 25, no. 6, pp. 842-850, 2002.
74. S. L. Xiong, Z. B. Wen, Q. Wang, X. F. He, and S. L. He, "Infu-ence of tetramethylpyrazine on the tissue factor expression induced by TNFα inendothelial cells," China Journal of Modern Medicine, vol. 17, no. 19, pp. 2330-2333, 2007.
75. G. P. Shang, Z. B. Wen, J. C. Li et al., "The efects of teteram-ethylpyrazine on the releases of von Wollebrand Factor, tissue factor pathway inhibitor and the expression of tissue iduced by thrombin in cultured bovine aortic endothelial cells," Journal of Changzhi Medical College, vol. 14, no. 1, pp. 1-3, 2000.
76. M. H. Lee, K. S. Yeon, and N. H. Yong, "Tissue factor inhibitory sesquiterpene glycoside from Eriobotrya japonica," Archives of Pharmacal Research, vol. 27, no. 6, pp. 619-623, 2004.
77. D. W. Schwertz and S. Penckofer, "Sex diferences and the efects of sex hormones on hemostasis and vascular reactivity," Heart & Lung, vol. 30, no. 6, pp. 401-426, 2001.
78. W. Wang, G. J. Zhu, and S. Y. Zu, "Efects of phytoestrogens α2 zearalanol on reducing tissue factor and nuclear transcription factors AP-1 and NF-kB levels," Chinese Journal of Circulation, vol. 14, no. 2, pp. 5-7, 2004.
79. H. Li, X. Y. Hao, T. X. Lei, and Y. Su, "Progress on anti-throm-botic experiments by traditional Chinese medicines," Journal of Traditional Chinese Medicine, vol. 26, no. 3, pp. 63-64, 2006.
80. Y. J. Hou, Studies on extraction, isolation, structural characterization and anticoagulant activity of the sulfated polysaccharides from green alga Monostroma arcticum [M.S. thesis], Ocean University of China, 2012.
81. J. P. Kou, J. F. Li, J. Yan, and D. N. Zhu, "Efect of total saponin from root of Polygala fallax Hesml. (PTS) on coagulation and thrombosis," Journal of China Pharmaceutical University, vol. 34, no. 3, pp. 63-65, 2003.
82. S. Ku, H. Yoo, W. Zhou, M. Na, and J. Bae, "Antiplatelet activities of hyperoside in vitro and in vivo," Animal Cells and Systems, vol. 18, no. 3, pp. 204-209, 2014.
83. Y. Wang, J. Shao, S. Yao et al., "Study on the antithrombotic activity of Umbilicaria esculenta polysaccharide," Carbohydrate Polymers, vol. 105, no. 1, pp. 231-236, 2014.
84. M. Kaileh, W. Vanden Berghe, A. Heyerick et al., "Withaferin A strongly elicits IαB kinase α hyperphosphorylation concomitant with potent inhibition of its kinase activity," Journal of Biological Chemistry, vol. 282, no. 7, pp. 4253-4264, 2007.
85. R. Mehta and A. D. Shapiro, "Plasminogen activator inhibitor type 1 defciency," Haemophilia, vol. 14, no. 6, pp. 1255-1260, 2008.
86. S. Ku and J. Bae, "Antiplatelet, anticoagulant, and profbrinolytic activities of withaferin A," Vascular Pharmacology, vol. 60, no. 3, pp. 120-126, 2014.
87. M. C. Tai, S. Y. Tsang, L. Y. F. Chang, and H. Xue, "Terapeutic potential of wogonin: a naturally occurring favonoid," CNS Drug Reviews, vol. 11, no. 2, pp. 141-150, 2005.
88. S. K. Ku and J. S. Bae, "Antithrombotic activities of wogonin and wogonoside via inhibiting platelet aggregation," Fitoterapia, vol. 98, pp. 27-35, 2014.
89. I. Pawlaczyk, L. Czerchawski, W. Kuliczkowski et al., "Anticoagulant and anti-platelet activity of polyphenolic-polysac-charide preparation isolated from the medicinal plant Erigeron canadensis L.," Trombosis Research, vol. 127, no. 4, pp. 328-340, 2011.
90. T. Pu, X. Y. Mo, and R. Z. Lin, "Study on the free radical- scavenging and anti-coagulant activities of total Paeony glyco-side in vitro," China Pharmacy, vol. 18, no. 9, pp. 643-646, 2007.
91. E. Amroyan, E. Gabrielian, A. Panossian, G. Wikman, and H. Wagner, "Inhibitory efect of andrographolide from Andro-graphis paniculata on PAF-induced platelet aggregation," Phy-tomedicine, vol. 6, no. 1, pp. 27-31, 1999.
92. Y. K. Sun and S. Y.-C. Hye, "Platelet anti-aggregating activities of bupleurumin from the aerial parts of Bupleurum falcatum," Archives of Pharmacal Research, vol. 30, no. 5, pp. 561-564, 2007.
93. F. Maione, V. de Feo, E. Caiazzo, L. de Martino, C. Cicala, and N. Mascolo, "Tanshinone IIA, a major component of Salvia milthorriza Bunge, inhibits platelet activation via Erk-2 signaling pathway," Journal of Ethnopharmacology, vol. 155, no. 2, pp. 1236-1242, 2014.
94. M. Yasin, K. Hussain Janbaz, I. Imran, A.-U. Gilani, and S. Bashir, "Pharmacological studies on the antispasmodic, bron-chodilator and anti-Platelet Activities of Abies webbiana," Phy-totherapy Research, vol. 28, no. 8, pp. 1182-1187, 2014.
95. D. Gadi, M. Bnouham, M. Aziz et al., "Parsley extract inhibits in vitro and ex vivo platelet aggregation and prolongs bleeding time in rats," Journal of Ethnopharmacology, vol. 125, no. 1, pp. 170-174, 2009.
96. S. P. Jackson and S. M. Schoenwaelder, "Antiplatelet therapy: in search of the 'magic bullet'," Nature Reviews Drug Discovery, vol. 2, no. 10, pp. 775-789, 2003.
97. Y.-H. Li, X.-P. Sun, Y.-Q. Zhang, and N.-S. Wang, "The anti-thrombotic efect of Borneol related to its anticoagulant property," The American Journal of Chinese Medicine, vol. 36, no. 4, pp. 719-727, 2008.
98. S.-X. Guan, Z.-W. Yuan, Y.-B. Zhou, Y. Zhang, X.-L. Ye, and B. Hu, "Comparative studies on anti-thrombus and anti-coagulation efects of Hirodu of diferent species," Chinese Hospital Parmaceutical Jounal, vol. 32, no. 14, pp. 1093-1096, 2012.
99. X. Y. Li, G. Y. Li, H. Y. Wang et al., "Study on anti-coagulation efect of Ferula lehmannii Boiss," China Pharmacist, vol. 13, no. 11, pp. 1626-1628, 2010.
100. X. T. Guo, X. J. Yang, and Y. Wang, "Study on anticoagulative efect of co-safower preparation," Xinjiang Agricultural Sciences, vol. 49, no. 9, pp. 1759-1763, 2012.
101. M. Wan, Study on oligopeptide with anticoagulant activity from Whilmania pigra Whitman [Ph.D. thesis], Hubei University of Chinese Medicine, 2012.
102. J. Li, Y. X. Wei, G. C. Du, Y. F. Hu, and L. Li, "Aanticoag-ulant activities of Phlorotannins from Sargassum thunbeergii Kuntze," Traditional Chinese Drug Research & Clinical Pharmacology, vol. 18, no. 3, pp. 191-194, 2007.
103. J. E. Zhang, X. L. Liu, J. Y. Yang, and C. C. Liu, "Study on anticoagulant activity of sulfated Polysaccharides from Hizikia fusiformis," Journal of Anhui Agricultural Sciences, vol. 36, no. 18, pp. 7505-7508, 2008.
104. P. V. Fernández, I. Quintana, A. S. Cerezo et al., "Anticoagulant activity of a unique sulfated pyranosic (1 → 3)-α-L-arabinan through direct interaction with thrombin," The Journal of Biological Chemistry, vol. 288, no. 1, pp. 223-233, 2013.
105. ′-tetrahydroxystil-bene-2-O-α-D-glucoside (THSG) attenuates human platelet aggregation, secretion and spreading in vitro," Trombosis Research, vol. 133, no. 2, pp. 211-217, 2014.
106. B.-J. Lee, I.-Y. Jo, Y. Bu et al., "Antiplatelet efects of Spatholobus suberectus via inhibition of the glycoprotein IIb/IIIa receptor," Journal of Ethnopharmacology, vol. 134, no. 2, pp. 460-467, 2011.
107. Y. Kong, J.-L. Huo, W. Xu, J. Xiong, Y.-M. Li, and W.-T. Wu, "A novel anti-platelet aggregation tripeptide from Agkistrodon acutus venom: isolation and characterization," Toxicon, vol. 54, no. 2, pp. 103-109, 2009.
108. W. Li, X. Tang, W. Yi et al., "Glaucocalyxin A inhibits platelet activation and thrombus formation preferentially via GPVI signaling pathway," PLoS ONE, vol. 8, no. 12, Article ID e85120, 2013.
109. C. Ma, Y. Yao, Q.-X. Yue et al., "Diferential proteomic analysis of platelets suggested possible signal cascades network in platelets treated with Salvianolic acid B," PLoS ONE, vol. 6, no. 2, Article ID e14692, 2011.
110. M.-K. Park, Y.-H. Rhee, H.-J. Lee et al., "Antiplatelet and anti-thrombotic activity of indole-3-carbinol in vitro and in vivo," Phytotherapy Research, vol. 22, no. 1, pp. 58-64, 2008.
111. J. Jalil, I. Jantan, A. A. Ghani, and S. Murad, "Platelet-activating factor (PAF) antagonistic activity of a new bifavonoid from Garcinia nervosa var. pubescens king," Molecules, vol. 17, no. 9, pp. 10893-10901, 2012.
112. B. A. Moharam, I. Jantan, F. B. Ahmad, and J. Jalil, "Antiplatelet aggregation and platelet activating factor (PAF) receptor antagonistic activities of the essential oils of fve Goniothalamus species," Molecules, vol. 15, no. 8, pp. 5124-5138, 2010.
113. G. L. Allison, G. M. Lowe, and K. Rahman, "Aged garlic extract inhibits platelet activation by increasing intracellular cAMP and reducing the interaction of GPIIb/IIIa receptor with fbrino-gen," Life Sciences, vol. 91, no. 25-26, pp. 1275-1280, 2012.
114. J.-R. Sheu, Y.-C. Kan, W.-C. Hung, W.-C. Ko, and M.-H. Yen, "Mechanisms involved in the antiplatelet activity of tetram-ethylpyrazine in human platelets," Trombosis Research, vol. 88, no. 3, pp. 259-270, 1997.
115. X. M. Fei, Y. Chen, W. F. Wu et al., "Efects of Agrrimoni Pilosa aqueous extract on platelet aggregation, coagulation function and hemorheology," Journal of Chinese Clinical Pharmacology and Terapeutics, vol. 18, no. 1, pp. 10-16, 2013.
116. J. Li and C. Chen, "Experimental study on antithrombosis activity of N-butanol extract of Toonasinensis seeds," Journal of Sichuan of Traditional Chinese Medicine, vol. 27, no. 5, pp. 26-29, 2009.
117. P. Stead, S. Hiscox, P. S. Robinson et al., "Eryloside F, a novel penasterol disaccharide possessing potent thrombin receptor antagonist activity," Bioorganic & Medicinal Chemistry Letters, vol. 10, no. 7, pp. 661-664, 2000.
118. W. K. Jeon, J. H. Lee, H. K. Kim et al., "Anti-platelet efects of bioactive compounds isolated from the bark of Rhus vernicifua Stokes," Journal of Ethnopharmacology, vol. 106, no. 1, pp. 62-69, 2006.
119. 2 receptor antagonist," European Journal of Pharmacology, vol. 570, no. 1-3, pp. 38-42, 2007.
120. W. K. Jeon, Y. E. Kim, S. O. Park et al., "The modifed Je-Ho-Tang, Korean herbal medicine, inhibits whole-blood aggregation and platelet adhesion to collagen under fow," Trombosis Research, vol. 122, no. 6, pp. 804-809, 2008.
121. C. Alvarado-Castillo, O. Estrada, and E. Carvajal, "Pomolic acid, triterpenoid isolated from Licania pittieri, as competitive antagonist of ADP-induced aggregation of human platelets," Phytomedicine, vol. 19, no. 6, pp. 484-487, 2012.
122. 2+ in the inhibition by crocetin of platelet activity and thrombosis formation," Journal of Agricultural and Food Chemistry, vol. 56, no. 20, pp. 9429-9433, 2008.
123. J.-J. Lee, T. Kim, W.-K. Cho, and J. Y. Ma, "Antithrombotic and antiplatelet activities of Soshiho-tang extract," BMC Complementary and Alternative Medicine, vol. 13, pp. 137-144, 2013.
124. 2+ mobilization in activated human platelets," Life Sciences, vol. 75, no. 25, pp. 3063-3076, 2004.
125. K. Kim, K.-M. Lim, C.-W. Kim et al., "Black soybean extract can attenuate thrombosis through inhibition of collagen-induced platelet activation," The Journal of Nutritional Biochemistry, vol. 22, no. 10, pp. 964-970, 2011.
126. T.-H. Tsai, W.-J. Tsai, C.-J. Chou, and C.-F. Chen, "Magnolol inhibits collagen-induced platelet serotonin release," Trombo-sis Research, vol. 78, no. 3, pp. 265-270, 1995.
127. R. Y. Zhao, W. Hao, X. J. Meng et al., "Efects of Ligustrazine Fer-ulate on thrombosis and platelet-neutrophil adhesion," Journal of China Medical University, vol. 41, no. 10, pp. 900-903, 2012.
128. Y. Y. Guo, S. Jiang, Q. Lin, and X. F. Li, "Anti-platelet aggregation function and mechanism of alcohol extracted from Gastrodia elata Blume," Lishizhen Medicine and Material Medical Research, vol. 25, no. 1, pp. 4-6, 2014.
129. X.-L. Xie, Q.-H. Gong, Y.-F. Lu et al., "Efect of rhynchophylline on platelet aggregation and cytoplasmic free calcium level in rabbits," Chinese Journal of Pharmacology and Toxicology, vol. 25, no. 1, pp. 68-71, 2011.
130. W. Li, J. P. Zhang, S. X. Xu, A. Q. Zhong, and S. Y. Hua, "Efects of salvianolic acid B on the platelet aggregation and sP-sel and sCD40L release," Chinese Archives of Traditional Chinese Medicines, vol. 2013, no. 1, pp. 48-50, 2013.
131. E. Fuentes, M. Alarcón, L. Astudillo, C. Valenzuela, M. Gutiérrez, and I. Palomo, "Protective mechanisms of guanosine from Solanum lycopersicum on agonist-induced platelet activation: role of sCD40L," Molecules, vol. 18, no. 7, pp. 8120-8135, 2013.
132. Q. Xia, X. Wang, D.-J. Xu, X.-H. Chen, and F.-H. Chen, "Inhibition of platelet aggregation by curdione from Curcuma wenyujin essential Oil," Trombosis Research, vol. 130, no. 3, pp. 409-414, 2012.
133. D.-H. Lee, Y.-J. Kim, H.-H. Kim et al., "Inhibitory efects of epigallocatechin-3-gallate on microsomal cyclooxygenase-1 activity in platelets," Biomolecules & Terapeutics, vol. 21, no. 1, pp. 54-59, 2013.
134. E. J. Seo, S. Y. Lee, S. S. Kang, and Y.-S. Jung, "Zizyphus jujuba and its active component jujuboside B inhibit platelet aggregation," Phytotherapy Research, vol. 27, no. 6, pp. 829-834, 2013.
135. 2 synthase," Journal of Ethnopharmacology, vol. 155, no. 1, pp. 285-292, 2014.
136. J.-Y. Yu, J.-J. Lee, J.-K. Jung et al., "Anti-platelet activity of diacetylated obovatol through regulating cyclooxygenase and lipoxygenase activities," Archives of Pharmacal Research, vol. 35, no. 12, pp. 2191-2198, 2012.
137. R. Ryu, U. J. Jung, H.-J. Kim et al., "Anticoagulant and anti-platelet activities of artemisia princes pampanini and its bioac-tive components," Preventive Nutrition and Food Science, vol. 18, no. 3, pp. 181-187, 2013.
138. C. G. Huang, Z. L. Chu, S. J. Wei, H. Jiang, and B. H. Jiao, "Efect of berberine on arachidonic acid metabolism in rabbit platelets and endothelial cells," Trombosis Research, vol. 106, no. 4-5, pp. 223-227, 2002.
139. Y.-R. Jin, X.-H. Han, Y.-H. Zhang et al., "Antiplatelet activity of hesperetin, a biofavonoid, is mainly mediated by inhibition of PLC-α2 phosphorylation and cyclooxygenase-1 activity," Atherosclerosis, vol. 194, no. 1, pp. 144-152, 2007.
140. D.-J. Son, M.-R. Cho, Y.-R. Jin et al., "Antiplatelet efect of green tea catechins: a possible mechanism through arachidonic acid pathway," Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 71, no. 1, pp. 25-31, 2004.
141. M. C. Chang, B. J. Uang, C. Y. Tsai et al., "Hydroxychavicol, a novel betel leaf component, inhibits platelet aggregation by suppression of cyclooxygenase, thromboxane production and calcium mobilization," British Journal of Pharmacology, vol. 152, no. 1, pp. 73-82, 2007.
142. 2 formation," Journal of Ethno-pharmacology, vol. 66, no. 2, pp. 241-246, 1999.
143. X.-L. Xie, M. Wu, Q. Wu, X.-N. Huang, Q.-H. Gong, and J.-S. Shi, "Efect of isorhynchophylline on platelet aggregation and thrombosis," Chinese Pharmaceutical Journal, vol. 43, no. 4, pp. 280-283, 2008.
144. W. L. Fan and D. Luo, "The antiplatelet aggregation mechanism of Genistein," Chinese Journal of Biochemical Pharmaceutics, vol. 33, no. 3, pp. 267-269, 2012.
145. Y.-L. Mu, X. Wang, J. Li, H.-X. Zhao, and H. Bai, "Study on promoting blood circulation by removing blood stasis of Cae-salpinia sappan L.," Chinese Pharmacological Bulletin, vol. 29, no. 10, pp. 1479-1480, 2013.
146. 2 afer platelet aggregation induced by adenosine diphosphate in rabbits," Chinese Journal of Rehabilitation Theory and Practice, vol. 18, no. 4, pp. 329-330, 2012.
147. P. L. Sun, S. R. Wei, X. F. Wang et al., "Efects of Morroniside on cycloxygenase afer platelet aggregation induced by adenosine diphosphate in rabbits," Chinese Journal of Rehabilitation Theory and Practice, vol. 18, no. 4, pp. 331-332, 2012.
148. E. D. Coy, L. E. Cuca, and M. Sefow, "COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans," Bioorganic & Medicinal Chemistry Letters, vol. 19, no. 24, pp. 6922-6925, 2009.
149. M. Abe, Y. Ozawa, Y. Uda, Y. Morimitsu, Y. Nakamura, and T. Osawa, "A novel labdane-type trialdehyde from myoga (Zin-giber mioga Roscoe) that potently inhibits human platelet aggregation and human 5-lipoxygenase," Bioscience, Biotechnology and Biochemistry, vol. 70, no. 10, pp. 2494-2500, 2006.
150. 1 reveals attenuated 12-HETE production," Journal of Proteome Research, vol. 11, no. 10, pp. 4939-4946, 2012.
151. G. Stoll, C. Kleinschnitz, and B. Nieswandt, "Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment," Blood, vol. 112, no. 9, pp. 3555-3562, 2008.
152. M.-H. Lee, Y.-P. Lin, F.-L. Hsu, G.-R. Zhan, and K.-Y. Yen, "Bioactive constituents of Spatholobus suberectus in regulating tyrosinase-related proteins and mRNA in HEMn cells," Phyto-chemistry, vol. 67, no. 12, pp. 1262-1270, 2006.
153. K. Rahman, "Efects of garlic on platelet biochemistry and physiology," Molecular Nutrition & Food Research, vol. 51, no. 11, pp. 1335-1344, 2007.
154. B. Zhang and K. Long, "Efects of glaucocalyxin A on aggregation and cAMP levels of rabbit platelets in vitro," Acta Pharmacologica Sinica, vol. 14, no. 4, pp. 347-350, 1993.
155. M. Yagi and N. Matsuura, "Maillard reaction product decomposition agents containing plant extracts and food containing the agents," Japanese Kokai Tokkyo Koho, JP 2007119373 A 20070517, 2007.
156. W. Zhang and R. W. Colman, "Trombin regulates intracellular cyclic AMP concentration in human platelets through phos-phorylation/activation of phosphodiesterase 3A," Blood, vol. 110, no. 5, pp. 1475-1482, 2007.
157. F. Y. Ali, M. G. Hall, B. Desvergne, T. D. Warner, and J. A. Mitchell, "PPAR beta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specifc association/repression of PKCalpha-brief report," Arteriosclerosis, Trombosis, and Vascular Biology, vol. 29, no. 11, pp. 1871-1873, 2009.
158. R. Feil, S. M. Lohmann, H. de Jonge, U. Walter, and F. Hofmann, "Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modifed mice," Circulation Research, vol. 93, no. 10, pp. 907-916, 2003.
159. H.-J. Cho, J. Y. Cho, M. H. Rhee, and H.-J. Park, "Cordycepin (3′-deoxyadenosine) inhibits human platelet aggregation in a cyclic AMP-and cyclic GMP-dependent manner," European Journal of Pharmacology, vol. 558, no. 1-3, pp. 43-51, 2007
160. 2+]α mobilization and fbrinogen binding via phosphoryla-tion of IP3R and VASP, Archives of Pharmacal Research, vol. 38, no. 1, pp. 81-97, 2015.
161. H.-J. Cho, Y.-H. Shon, and K.-S. Nam, "Ginkgolide C inhibits platelet aggregation in cAMP-and cGMP-dependent manner by activating MMP-9," Biological & Pharmaceutical Bulletin, vol. 30, no. 12, pp. 2340-2344, 2007
162. P. Tan, Y Hao, Y Liu, K. R. Peng, and S. J. Ding, "Efects of the main monomer ingredients of Ginkgo biloba extract on phosphodiesterase 3 activity of platelet," Chinese Journal of Clinical Physicians, vol. 7, no. 24, pp. 11569-11573, 2013.
163. P. Gresele, S. Momi, and E. Falcinelli, "Anti-platelet therapy: phosphodiesterase inhibitors," British Journal of Clinical Pharmacology, vol. 72, no. 4, pp. 634-646, 2011.
164. J. Y Park, W. J. Oh, M. J. Kim et al., "Mechanism of anti-platelet activity of Oligoporus tephroleucus oligoporin A: involvement of extracellular signal-regulated kinase phosphorylation and cyclic nucleotide elevation," Platelets, vol. 23, no. 5, pp. 376-385, 2012.
165. S. P. Jackson, W. S. Nesbitt, and S. Kulkarni, "Signaling events underlying thrombus formation," Journal of Trombosis and Haemostasis, vol. 1, no. 7, pp. 1602-1612, 2003.
166. K. Y Ho, C. C. Tsai, C. P. Chen et al., "Antimicrobial activity of honokiol and magnolol isolated from Magnolia ofcinalis," Phytotherapy Research, vol. 15, no. 2, pp. 139-141, 2001.
167. 2 production and cyclooxy-genase-2 expression by curdione from Curcuma zedoaria" Archives of Pharmacal Research, vol. 30, no. 10, pp. 1226-1239, 2007
168. C. Patrono, P. Patrignani, and L. A. García Rodríguez, "Cyclo oxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs," The Journal of Clinical Investigation, vol. 108, no. 1, pp. 7-13, 2001.
169. K. F. Standeven, R. A. S. Ariens, and P. J. Grant, "The molecular physiology and pathology of fbrin structure/function," Blood Reviews, vol. 19, no. 5, pp. 275-288, 2005.
170. H.-P. Li, Z. Hu, J.-L. Yuan et al., "A novel extracellular protease with fbrinolytic activity from the culture supernatant of Cordyceps sinensis: purifcation and characterization," Phytotherapy Research, vol. 21, no. 12, pp. 1234-1241, 2007
171. Y Peng, Q. Huang, R.-H. Zhang, and Y.-Z. Zhang, "Purifcation and characterization of a fbrinolytic enzyme produced by Bacillus amyloliquefaciens DC-4 screened from douchi, a traditional Chinese soybean food," Comparative Biochemistry and Physiology B-Biochemistry and Molecular Biology, vol. 134, no. 1, pp. 45-52, 2003.
172. H. Mihara, H. Sumi, T. Yoneta et al., "A novel fbrinolytic enzyme extracted from the earthworm, Lumbricus rubellus," Japanese Journal of Physiology, vol. 41, no. 3, pp. 461-472, 1991.
173. X. Z. Zhao, Extraction, Isolation, Purifcation, Biological Active of Earthworm Fibrinolytic Enzymes and Compound Amino Acid from Errthworm, Xihua University, 2012.
174. Y. Xiong, S. C. Yang, X. Y. Liu, L. Y. Li, and B. G. Ru, "Purifcation and determination of partial sequence of earthworm fbri-nolytic enzyme," Chinese Biochemical Journal, vol. 13, no. 3, pp. 292-296, 1997.
175. J. Huang, L.-H. Mei, S. Hu et al., "Screening of bacillus subtilis natto from traditional Japanese food natto and separation of nattokinase," Journal of Chemical Engineering of Chinese Universities, vol. 19, no. 4, pp. 518-522, 2005.
176. Z. W. Chen, E. N. Xu, and M. Y. Xiao, "The research progress of nattokinase," Food Science, vol. 23, no. 10, pp. 130-134, 2002.
177. G. Park, D. P. Paudyal, Y. Park et al., "Efects of pine needle extracts on plasma cholesterol, fbrinolysis and gastrointestinal motility," Biotechnology and Bioprocess Engineering, vol. 13, no. 2, pp. 262-268, 2008.
178. C. B. Huang, X. J. Pan, L. Tang, C. N. Chen, and C. H. He, "Experimental studies in vitro fbrinolytic activities about six kinds of authentic medicinal materials from Guangxi," Progress in Modern Biomedicine, vol. 13, no. 31, pp. 6043-6047, 2013.
179. W. Lu, W. H. Wu, P. G. Zhou, and B. Bao, "Isolation and identi-fcation of two compounds of enhancing fbrinolysis from Sar-gassum fulvellum," Natural Products, vol. 21, no. 5, pp. 787-791, 2009.